JILL NATALE: Open Payments
NPI 1982866174 · UNIONTOWN, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$557 in 29 payments from 13 companies in 2025. Trend: 2023 $89 · 2024 $245 · 2025 $557
Food & beverage: $557
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 5 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Lilly USA, LLC | 3 | $64 |
| AstraZeneca Pharmaceuticals LP | 4 | $57 |
| ABBVIE INC. | 2 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $35 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $33 |
| Abbott Laboratories | 1 | $20 |
Products named: REXULTI, TRELEGY ELLIPTA, MOUNJARO, FARXIGA, FANAPT, DUPIXENT, SHINGRIX, Kerendia.
Industry payments across PA — which companies pay providers there.
